Literature DB >> 9345424

Remyelination of the central nervous system.

A Compston1.   

Abstract

The three typical stages in the clinical course of multiple sclerosis (relapse, persistent disability and progression) can be explained on the basis of inflammation, demyelination and failure of repair leading to axon degeneration and astrocytosis. Strategies are being evaluated for limiting the inflammatory process using immunological treatments and these may have unexpected dividends in promoting endogenous remyelination. Increasing knowledge on glial lineages and axon-glial interactions needed for stable myelination also offer the prospect for enhancing remyelination through growth factor therapy and cell implantation.

Entities:  

Mesh:

Year:  1996        PMID: 9345424     DOI: 10.1177/135245859600100622

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  10 in total

1.  Cerebrospinal fluid analysis differentiates between relapsing-remitting and secondary progressive multiple sclerosis.

Authors:  P J Jongen; K J Lamers; W H Doesburg; W A Lemmens; O R Hommes
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-10       Impact factor: 10.154

Review 2.  Cell therapy in demyelinating diseases.

Authors:  Claire Rice; Christopher Halfpenny; Neil Scolding
Journal:  NeuroRx       Date:  2004-10

Review 3.  Strategies for achieving and monitoring myelin repair.

Authors:  Claire Rice; Neil Scolding
Journal:  J Neurol       Date:  2007-03-07       Impact factor: 4.849

Review 4.  Cell therapy for multiple sclerosis.

Authors:  Tamir Ben-Hur
Journal:  Neurotherapeutics       Date:  2011-10       Impact factor: 7.620

5.  Insulin-like growth factor-1 inhibits mature oligodendrocyte apoptosis during primary demyelination.

Authors:  J L Mason; P Ye; K Suzuki; A J D'Ercole; G K Matsushima
Journal:  J Neurosci       Date:  2000-08-01       Impact factor: 6.167

Review 6.  Neuroprotection in multiple sclerosis: a therapeutic approach.

Authors:  Amir-Hadi Maghzi; Alireza Minagar; Emmanuelle Waubant
Journal:  CNS Drugs       Date:  2013-10       Impact factor: 5.749

Review 7.  Therapeutic strategies in multiple sclerosis. II. Long-term repair.

Authors:  N Scolding
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-10-29       Impact factor: 6.237

8.  Neurofilament proteins as body fluid biomarkers of neurodegeneration in multiple sclerosis.

Authors:  Melissa M Gresle; Helmut Butzkueven; Gerry Shaw
Journal:  Mult Scler Int       Date:  2011-01-23

Review 9.  Neuro-immune interactions of neural stem cell transplants: from animal disease models to human trials.

Authors:  Elena Giusto; Matteo Donegà; Chiara Cossetti; Stefano Pluchino
Journal:  Exp Neurol       Date:  2013-03-16       Impact factor: 5.330

10.  Leukemia inhibitory factor protects axons in experimental autoimmune encephalomyelitis via an oligodendrocyte-independent mechanism.

Authors:  Melissa M Gresle; Estella Alexandrou; Qizhu Wu; Gary Egan; Vilija Jokubaitis; Margaret Ayers; Anna Jonas; William Doherty; Anna Friedhuber; Gerry Shaw; Michael Sendtner; Ben Emery; Trevor Kilpatrick; Helmut Butzkueven
Journal:  PLoS One       Date:  2012-10-15       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.